Combined application of vaccine that contains RM-1 cells which expressed 4-1BBL with CTLA-4 blockade can induce the regression of prostate cancer cells, showing the treatment potency of 4-1BBL in cancer immunotherapy (69). The gene discussed is CTLA4; the disease is prostate carcinoma.